
OPN and ACCP Hematology/Oncology PRN Journal Club - August 2026
- The OPN and the ACCP H/O PRN Journal Club is a monthly virtual (online) event.
Overview
The phase III KEYNOTE-689 trial is the first study in more than 20 years to demonstrate improved outcomes over standard-of-care treatment for patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). By evaluating perioperative pembrolizumab in addition to standard-of-care versus standard-of-care alone, this study addressed a significant unmet need in a disease setting where recurrence rates remain high despite multimodal treatment.
This presentation will summarize the current management of locally advanced HNSCC, discuss the rationale for perioperative immunotherapy, and review the KEYNOTE-689 study including efficacy and safety outcomes, clinical implications, limitations, and potential impact on future treatment strategies.
Identified Gap(s)
Oncology pharmacists lack regular, structured opportunities to engage with emerging literature and apply new evidence to clinical practice. The rapid pace of drug development, evolving treatment guidelines, and increasing complexity of oncology care demand ongoing education that is interactive and peer driven. The absence of oncology-specific journal clubs limits pharmacists’ ability to stay current, critically evaluate research, and contribute fully to multidisciplinary care—ultimately impacting patient outcomes.
Description of Current State
Oncology pharmacists are increasingly stepping into high-value, patient-focused roles due to the growing complexity of cancer care and shortages of oncologists and nurses. With over 50 new cancer drugs approved in 2024 alone, the need for pharmacists to stay current with treatment advances is critical.1 However, educational gaps persist, as pharmacists often lack access to oncology-focused continuing education. As drug experts on the care team, they must be equipped to manage complex therapies and fill care gaps—particularly in areas like pregnancy-associated cancer and supportive care.
Description of desired/achievable state
Oncology pharmacists will have access to a virtual, accredited journal club designed to support continuous learning and clinical application of emerging evidence. This interactive platform will foster peer-to-peer discussion, enhance critical literature appraisal skills, and empower pharmacists to deliver evidence-based care in complex scenarios, ultimately strengthening their role within the oncology care team.
Upon completion of this journal club, you will:
- Discuss potential sources of bias, limitations, and strengths of each clinical study
- Assess the validity, relevance, and applicability of the latest clinical research studies
Target Audience
This activity is intended for oncology pharmacists, pharmacy techs, and pharmacy residents who are involved in the treatment of cancer patients.
Presented By
Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
All Times Listed are for the Eastern Standard Time Zone
| Thursday, August 20, 2026 | |
|---|---|
| 3:00pm | Welcome and Introduction » Julia Lea Ziegengeist, PharmD, BCOP |
| 3:05pm | OPN and ACCP Hematology/Oncology PRN Journal Club - August 2026 » Alexis Goggin, PharmD |
| 3:35am | Breakout Room + Closing Comments » Julia Lea Ziegengeist, PharmD, BCOP |
Faculty

Julia Lea Ziegengeist, PharmD, BCOP (Moderator)
Clinical Pharmacist Specialist,
Breast Medical Oncology, Pharmacy Services
Levine Cancer, Barbara L. Levine Oncology Breast & Cutaneous Center
Charlotte, NC
Dr. Julia Ziegengeist practices as a Clinical Pharmacist Specialist for solid tumor oncology specializing in breast cancer at Atrium Health Levine Cancer in Charlotte, North Carolina. She completed her PGY-1 Pharmacy Residency and PGY-2 Oncology Pharmacy Residency at Virginia Commonwealth University in Richmond, Virginia in 2018 and 2019, respectively. Since completion of residency, her primary oncology practice site has been within the Levine Cancer Institute Breast Medical Oncology Clinic, where she works alongside providers and APPs to ensure quality cancer care by tailoring treatment options and subsequent toxicity management to individual patients. She is a board-certified oncology pharmacist and her professional interests include patient education, toxicity management, and expansion of clinical pharmacy services within oncology.

Alexis Goggin, PharmD, (Speaker)
PGY2 Heme/Onc Pharmacy Resident
Rush University Medical Center
Chicago, IL
Alexis (Lexi) Goggin is a PGY2 Hematology/Oncology Pharmacy Resident at Rush University Medical Center in Chicago, Illinois. She recently completed her PGY1 residency at Rush University Medical Center and earned her PharmD from the University of Illinois Chicago Retzky College of Pharmacy. Her clinical interests include hematological malignancies and hematopoietic stem cell transplantation, and she is passionate about precepting and mentoring pharmacy learners.
As a lifelong Chicagoan, Lexi enjoys taking advantage of the city’s summer with walks around Chicago’s many neighborhoods and beaches as well as exploring local food festivals. She also enjoys international travel when possible and values spending quality time with friends and family. Her dream is to travel to Japan someday so she can eat as much ramen and sushi as she wants without anyone judging her.
Program Planners

Julia Lea Ziegengeist, PharmD, BCOP
Clinical Pharmacist Specialist,
Breast Medical Oncology, Pharmacy Services
Levine Cancer, Barbara L. Levine Oncology Breast & Cutaneous Center
Charlotte, NC
Dr. Julia Ziegengeist practices as a Clinical Pharmacist Specialist for solid tumor oncology specializing in breast cancer at Atrium Health Levine Cancer in Charlotte, North Carolina. She completed her PGY-1 Pharmacy Residency and PGY-2 Oncology Pharmacy Residency at Virginia Commonwealth University in Richmond, Virginia in 2018 and 2019, respectively. Since completion of residency, her primary oncology practice site has been within the Levine Cancer Institute Breast Medical Oncology Clinic, where she works alongside providers and APPs to ensure quality cancer care by tailoring treatment options and subsequent toxicity management to individual patients. She is a board-certified oncology pharmacist and her professional interests include patient education, toxicity management, and expansion of clinical pharmacy services within oncology.

Marshall Winget, PharmD, BCOP
Inpatient Clinical Pharmacist
Malignant Hematology/Bone Marrow Transplant
Duke University Hospital, Durham
Durham, NC
Marshall Winget is a malignant hematology inpatient clinical pharmacist at Duke University Hospital. He earned his undergraduate degree from the University of Minnesota and his Doctor of Pharmacy from the University of North Carolina Eshelman School of Pharmacy. He then completed his PGY1 Pharmacy Practice Residency and PGY2 Oncology Pharmacy Residency at Vanderbilt University Medical Center in Nashville, Tennessee. His professional interests and research focus on lymphomas, cellular therapies, and cardio-oncology.

Shawn Griffin
Oncology Pharmacist/Assistant Clinical Professor
University of California, Irvine
Irvine, California
Shawn Griffin is a Board Certified Oncology Pharmacist and Health Sciences Assistant Clinical Professor in the Department of Clinical Pharmacy Practice at the University of California, Irvine (UCI) School of Pharmacy & Pharmaceutical Sciences. He practices within the Hematopoietic Stem Cell Transplantation and Cellular Therapy Program at the Chao Family Comprehensive Cancer Center. Prior to joining UCI, Griffin worked as a Hematology/Stem Cell Transplant pharmacist at Indiana University Health for five years. He received PharmD from the UNC Eshelman School of Pharmacy and completed a PGY1 Pharmacy and PGY2 Oncology Pharmacy Residency at the University of Florida Health Shands Hospital.
Disclosures
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
Planners
*Horizon CME has mitigated and resolved all relevant financial relationships
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
Horizon CME designates this Live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Required Hardware/software
Access to the internet is required.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
How to obtain credit for attendance (eligibility requirement and process for obtaining certificate)
To receive documentation of credit, participants must:
Login to the educational portal
Attend the educational activity
Complete the online evaluation form. The last day to access the evaluation is September 21, 2026 at 11:59pm PST*
Attest to the number of hours in attendance in order to generate your certificate
*Requests from learners to claim credit after the evaluation closes will not be granted

Facebook
X
LinkedIn
Forward